Labcorp Launches New Global Trial Connect Enhancements to Streamline Site Workflow
Latest updates improve site efficiency and are driven by insights gained through continued collaboration across sponsors and sites
BURLINGTON, N.C. (November 12, 2024) — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, announced today enhancements to Global Trial Connect, a suite of digital, data and operational solutions available to Labcorp Central Laboratory clients aimed at increasing the speed of clinical trials at the heart of clinical research – investigator sites.
"The latest enhancements to Global Trial Connect center on improving site workflow facilitation, which is critical to streamlining study execution and enabling sites to focus on their patients,” said Ryan Baehl, vice president, global operations, Central Laboratory Services at Labcorp. “By integrating sample collection and tracking data, we’re empowering earlier decision-making and providing actionable analytics that help both sites and sponsors reduce queries and improve protocol compliance. This is the latest update in our roadmap to address delivery efficiency across the entire clinical trial lifecycle and redefine how we deliver our industry-leading global laboratory services.”
Recent enhancements in the latest release of Global Trial Connect aim to reduce investigator site burden and improve sponsor oversight with a single point of access via the Labcorp Investigator Site and Sponsor Portals, respectively. These updates include:
● Sample Tracking, which facilitates more timely decision-making with earlier visibility into a sample’s chain of custody from registration through receipt by our laboratories. It also enables access to critical details to proactively manage the process with customizable views and reports.
● Electronic Requisition, which eliminates paper forms and reduces queries – up to 70% based on early studies where it has been deployed – with fully digital workflows and operational instructions for easier access, filing and reference. This is available across a wide variety of workflows, including those with complex sampling such as anatomic pathology, histology and home health visits.
Building on current supply efficiency improvements, the next Global Trial Connect release will focus on supply readiness, including user-driven modifications to kit ordering and supply management.
To learn more about Global Trial Connect, visit https://www.labcorp.com/biopharma/central-labs/global-trial-connect.
About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's more than 67,000 employees serve clients in approximately 100 countries, provided support for 84% of the new drugs and therapeutic products approved in 2023 by the FDA, and performed more than 600 million tests for patients around the world. Learn more about us at www.labcorp.com.
SOURCE
Christin O'Donnell (investors), [email protected]; Kimbrel Arculeo (media), [email protected]